Symbols / FULC
FULC Chart
About
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 566.03M |
| Enterprise Value | 395.72M | Income | -71.11M | Sales | — |
| Book/sh | 3.67 | Cash/sh | 3.71 | Dividend Yield | — |
| Payout | 0.00% | Employees | 45 | IPO | — |
| P/E | — | Forward P/E | -5.32 | PEG | — |
| P/S | inf | P/B | 2.34 | P/C | — |
| EV/EBITDA | -4.94 | EV/Sales | — | Quick Ratio | 17.33 |
| Current Ratio | 17.70 | Debt/Eq | 3.53 | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -1.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-24 | ROA | -20.63% |
| ROE | -31.21% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 65.97M |
| Shs Float | 33.83M | Short Float | 7.85% | Short Ratio | 4.91 |
| Short Interest | — | 52W High | 15.74 | 52W Low | 2.31 |
| Beta | 3.18 | Avg Volume | 1.33M | Volume | 4.15M |
| Target Price | $18.56 | Recom | Buy | Prev Close | $10.89 |
| Price | $8.58 | Change | -21.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$18.56
Mean price target
2. Current target
$8.58
Latest analyst target
3. DCF / Fair value
$-9.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.58
Low
$7.00
High
$25.00
Mean
$18.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | init | JP Morgan | — → Overweight | $20 |
| 2025-12-11 | main | Truist Securities | Buy → Buy | $18 |
| 2025-12-09 | main | B of A Securities | Underperform → Underperform | $7 |
| 2025-12-08 | main | RBC Capital | Sector Perform → Sector Perform | $10 |
| 2025-12-08 | main | Cantor Fitzgerald | Overweight → Overweight | $24 |
| 2025-12-08 | reit | Piper Sandler | Overweight → Overweight | $23 |
| 2025-12-08 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-24 | init | Truist Securities | — → Buy | $14 |
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-10-30 | main | RBC Capital | Sector Perform → Sector Perform | $7 |
| 2025-10-30 | reit | Piper Sandler | Overweight → Overweight | $16 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-07-30 | main | RBC Capital | Sector Perform → Sector Perform | $5 |
| 2025-07-29 | up | HC Wainwright & Co. | Neutral → Buy | $12 |
| 2025-05-29 | main | Piper Sandler | Overweight → Overweight | $9 |
| 2025-05-23 | up | Leerink Partners | Market Perform → Outperform | $12 |
| 2025-05-15 | up | Cantor Fitzgerald | Neutral → Overweight | $10 |
| 2025-02-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2024-11-14 | reit | RBC Capital | Sector Perform → Sector Perform | $4 |
| 2024-11-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
- FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings - Quiver Quantitative ue, 24 Feb 2026 12
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - Stock Titan ue, 24 Feb 2026 12
- What's Going On With Fulcrum Therapeutics Stock Tuesday? - Benzinga ue, 24 Feb 2026 14
- Stifel reiterates Fulcrum Therapeutics stock rating on drug data - Investing.com Nigeria ue, 24 Feb 2026 17
- Fulcrum Therapeutics (FULC) Shares Experience Unexpected Decline - GuruFocus ue, 24 Feb 2026 15
- $FULC stock is down 12% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 14
- Fulcrum Q4 Loss Widens; Reports Positive Phase 1b PIONEER Trial 12 Week Data Of Pociredir In SCD - Nasdaq ue, 24 Feb 2026 14
- Fulcrum Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat ue, 24 Feb 2026 18
- Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside - DirectorsTalk Interviews hu, 19 Feb 2026 14
- BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7 - Investing.com ue, 24 Feb 2026 18
- Positive Developments in Fulcrum Therapeutics (FULC) Boost Inves - GuruFocus ue, 24 Feb 2026 17
- 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga ue, 24 Feb 2026 17
- Leerink reiterates Fulcrum Therapeutics stock rating on SCD data - Investing.com ue, 24 Feb 2026 19
- Fulcrum Therapeutics stock tumbles despite trial results - Investing.com UK ue, 24 Feb 2026 12
- Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com India ue, 24 Feb 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | 160857 | — | Sale at price 10.72 per share. | GOULD ROBERT J. | Director | — | 2026-02-02 00:00:00 | D |
| 1 | 15000 | 178089 | — | Sale at price 11.87 per share. | GOULD ROBERT J. | Director | — | 2026-01-02 00:00:00 | D |
| 2 | 15000 | 163089 | — | Sale at price 10.87 per share. | GOULD ROBERT J. | Director | — | 2026-01-02 00:00:00 | D |
| 3 | 3452 | 44600 | — | Sale at price 12.92 per share. | OLTMANS CURTIS GALE | Officer | — | 2025-12-15 00:00:00 | D |
| 4 | 4175139 | 58377021 | — | Sale at price 13.33 - 14.98 per share. | RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-08 00:00:00 | I |
| 5 | 15000 | 165495 | — | Sale at price 11.03 per share. | GOULD ROBERT J. | Director | — | 2025-11-19 00:00:00 | D |
| 6 | 498 | 2520 | — | Sale at price 5.06 per share. | TOURANGEAU GREG | Officer | — | 2025-05-08 00:00:00 | D |
| 7 | 150000 | 490500 | — | Conversion of Exercise of derivative security at price 3.27 per share. | SAPIR ALEX | Chief Executive Officer | — | 2024-07-03 00:00:00 | D |
| 8 | 236 | 1831 | — | Sale at price 7.76 per share. | TOURANGEAU GREG | Officer | — | 2024-05-07 00:00:00 | D |
| 9 | 4884 | 57219 | — | Sale at price 11.72 per share. | TOURANGEAU GREG | Officer | — | 2024-03-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.18M | -108.49M | -109.29M | -78.54M |
| TotalUnusualItems | -2.06M | 0.00 | -427.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -2.06M | 0.00 | -427.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.72M | -97.33M | -109.87M | -80.85M |
| ReconciledDepreciation | 1.59M | 2.17M | 2.41M | 2.52M |
| EBITDA | -18.24M | -108.49M | -109.72M | -78.54M |
| EBIT | -19.83M | -110.66M | -112.13M | -81.05M |
| NormalizedIncome | -7.66M | -97.33M | -109.44M | -80.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.72M | -97.33M | -109.87M | -80.85M |
| TotalExpenses | 99.83M | 113.47M | 118.48M | 100.22M |
| TotalOperatingIncomeAsReported | -21.90M | -110.66M | -112.56M | -81.05M |
| DilutedAverageShares | 61.98M | 61.31M | 44.99M | 35.36M |
| BasicAverageShares | 61.98M | 61.31M | 44.99M | 35.36M |
| DilutedEPS | -0.16 | -1.59 | -2.44 | -2.29 |
| BasicEPS | -0.16 | -1.59 | -2.44 | -2.29 |
| DilutedNIAvailtoComStockholders | -9.72M | -97.33M | -109.87M | -80.85M |
| NetIncomeCommonStockholders | -9.72M | -97.33M | -109.87M | -80.85M |
| NetIncome | -9.72M | -97.33M | -109.87M | -80.85M |
| NetIncomeIncludingNoncontrollingInterests | -9.72M | -97.33M | -109.87M | -80.85M |
| NetIncomeContinuousOperations | -9.72M | -97.33M | -109.87M | -80.85M |
| PretaxIncome | -9.72M | -97.33M | -109.87M | -80.85M |
| OtherIncomeExpense | 10.11M | 13.33M | 2.26M | 207.00K |
| OtherNonOperatingIncomeExpenses | 12.17M | 13.33M | 2.69M | 207.00K |
| SpecialIncomeCharges | -2.06M | 0.00 | -427.00K | 0.00 |
| RestructuringAndMergernAcquisition | 2.06M | 0.00 | 427.00K | 0.00 |
| OperatingIncome | -19.83M | -110.66M | -112.13M | -81.05M |
| OperatingExpense | 99.83M | 113.47M | 118.48M | 100.22M |
| ResearchAndDevelopment | 63.39M | 71.80M | 76.78M | 69.70M |
| SellingGeneralAndAdministration | 36.45M | 41.67M | 41.69M | 30.52M |
| GeneralAndAdministrativeExpense | 36.45M | 41.67M | 41.69M | 30.52M |
| OtherGandA | 16.69M | 16.86M | 18.21M | 30.52M |
| SalariesAndWages | 19.75M | 24.81M | 23.49M | 14.80M |
| TotalRevenue | 80.00M | 2.81M | 6.34M | 19.16M |
| OperatingRevenue | 80.00M | 2.81M | 6.34M | 19.16M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 53.97M | 61.92M | 52.10M | 40.63M |
| ShareIssued | 53.97M | 61.92M | 52.10M | 40.63M |
| TotalDebt | 8.63M | 10.82M | 13.42M | 0.00 |
| TangibleBookValue | 243.03M | 235.19M | 198.94M | 211.54M |
| InvestedCapital | 243.03M | 235.19M | 198.94M | 211.54M |
| WorkingCapital | 238.88M | 228.52M | 190.79M | 206.80M |
| NetTangibleAssets | 243.03M | 235.19M | 198.94M | 211.54M |
| CapitalLeaseObligations | 8.63M | 10.82M | 13.42M | 0.00 |
| CommonStockEquity | 243.03M | 235.19M | 198.94M | 211.54M |
| TotalCapitalization | 243.03M | 235.19M | 198.94M | 211.54M |
| TotalEquityGrossMinorityInterest | 243.03M | 235.19M | 198.94M | 211.54M |
| StockholdersEquity | 243.03M | 235.19M | 198.94M | 211.54M |
| GainsLossesNotAffectingRetainedEarnings | 130.00K | -136.00K | -797.00K | -397.00K |
| OtherEquityAdjustments | 130.00K | -136.00K | -797.00K | -397.00K |
| TreasuryStock | 0.00 | 0.00 | ||
| RetainedEarnings | -519.40M | -509.67M | -412.34M | -302.47M |
| AdditionalPaidInCapital | 762.25M | 744.94M | 612.02M | 514.36M |
| CapitalStock | 54.00K | 62.00K | 52.00K | 41.00K |
| CommonStock | 54.00K | 62.00K | 52.00K | 41.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 17.68M | 22.50M | 27.74M | 23.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.64M | 8.83M | 11.02M | 4.26M |
| OtherNonCurrentLiabilities | 197.00K | 197.00K | 197.00K | |
| NonCurrentDeferredLiabilities | 0.00 | 4.26M | ||
| NonCurrentDeferredRevenue | 0.00 | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 6.44M | 8.63M | 10.82M | 0.00 |
| LongTermCapitalLeaseObligation | 6.44M | 8.63M | 10.82M | 0.00 |
| CurrentLiabilities | 11.04M | 13.68M | 16.73M | 19.20M |
| OtherCurrentLiabilities | 463.00K | 396.00K | 105.00K | 74.00K |
| CurrentDeferredLiabilities | 0.00 | 934.00K | 5.18M | |
| CurrentDeferredRevenue | 0.00 | 934.00K | 4.71M | |
| CurrentDebtAndCapitalLeaseObligation | 2.19M | 2.19M | 2.60M | |
| CurrentCapitalLeaseObligation | 2.19M | 2.19M | 2.60M | 0.00 |
| PayablesAndAccruedExpenses | 8.39M | 11.09M | 13.08M | 13.95M |
| CurrentAccruedExpenses | 7.23M | 8.33M | 9.45M | 9.16M |
| Payables | 1.16M | 2.76M | 3.64M | 4.79M |
| AccountsPayable | 1.16M | 2.76M | 3.64M | 4.79M |
| TotalAssets | 260.72M | 257.69M | 226.69M | 235.00M |
| TotalNonCurrentAssets | 10.79M | 15.49M | 19.17M | 9.00M |
| OtherNonCurrentAssets | 1.21M | 3.10M | 3.20M | 1.63M |
| NetPPE | 9.58M | 12.39M | 15.97M | 7.37M |
| AccumulatedDepreciation | -14.26M | -12.76M | -10.66M | -8.27M |
| GrossPPE | 23.84M | 25.15M | 26.63M | 15.64M |
| Leases | 7.12M | 7.10M | 7.10M | 6.29M |
| ConstructionInProgress | 0.00 | 31.00K | 0.00 | |
| OtherProperties | 15.53M | 16.86M | 18.12M | 8.18M |
| MachineryFurnitureEquipment | 1.19M | 1.19M | 1.38M | 1.17M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 249.92M | 242.20M | 207.52M | 226.00M |
| PrepaidAssets | 5.56M | 3.73M | 3.52M | 3.73M |
| Receivables | 3.34M | 2.25M | 1.08M | 4.11M |
| OtherReceivables | 2.10M | 537.00K | 229.00K | 1.14M |
| AccruedInterestReceivable | 1.25M | 1.71M | 852.00K | 473.00K |
| AccountsReceivable | 0.00 | 2.50M | ||
| CashCashEquivalentsAndShortTermInvestments | 241.02M | 236.22M | 202.92M | 218.16M |
| OtherShortTermInvestments | 182.81M | 210.66M | 167.82M | 182.75M |
| CashAndCashEquivalents | 58.21M | 25.56M | 35.10M | 35.41M |
| CashEquivalents | 58.21M | 25.56M | 35.10M | 35.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.50M | -91.47M | -99.01M | -80.19M |
| RepaymentOfDebt | 0.00 | -18.00K | ||
| IssuanceOfCapitalStock | 0.00 | 117.34M | 80.80M | 182.86M |
| CapitalExpenditure | -278.00K | -508.00K | -1.96M | -1.71M |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 59.41M | 26.66M | 36.19M | 36.50M |
| BeginningCashPosition | 26.66M | 36.19M | 36.50M | 58.14M |
| ChangesInCash | 32.76M | -9.54M | -314.00K | -21.64M |
| FinancingCashFlow | 2.75M | 118.12M | 84.32M | 186.51M |
| CashFlowFromContinuingFinancingActivities | 2.75M | 118.12M | 84.32M | 186.51M |
| ProceedsFromStockOptionExercised | 2.75M | 777.00K | 3.52M | 3.67M |
| NetCommonStockIssuance | 0.00 | 117.34M | 80.80M | 182.86M |
| CommonStockIssuance | 0.00 | 117.34M | 80.80M | 182.86M |
| NetIssuancePaymentsOfDebt | 0.00 | -18.00K | ||
| NetLongTermDebtIssuance | 0.00 | -18.00K | ||
| LongTermDebtPayments | 0.00 | -18.00K | ||
| InvestingCashFlow | 32.23M | -36.69M | 12.41M | -129.67M |
| CashFlowFromContinuingInvestingActivities | 32.23M | -36.69M | 12.41M | -129.67M |
| NetInvestmentPurchaseAndSale | 32.51M | -36.18M | 14.38M | -127.96M |
| SaleOfInvestment | 211.10M | 158.71M | 165.53M | 88.28M |
| PurchaseOfInvestment | -178.59M | -194.89M | -151.15M | -216.23M |
| NetPPEPurchaseAndSale | -278.00K | -508.00K | -1.96M | -1.71M |
| PurchaseOfPPE | -278.00K | -508.00K | -1.96M | -1.71M |
| OperatingCashFlow | -2.22M | -90.97M | -97.05M | -78.48M |
| CashFlowFromContinuingOperatingActivities | -2.22M | -90.97M | -97.05M | -78.48M |
| ChangeInWorkingCapital | -4.25M | -4.61M | -3.09M | -11.89M |
| ChangeInOtherWorkingCapital | -700.00K | -1.65M | -4.15M | -13.61M |
| ChangeInOtherCurrentAssets | 2.00M | 94.00K | -1.56M | 36.00K |
| ChangeInPayablesAndAccruedExpense | -2.62M | -1.68M | -621.00K | 2.92M |
| ChangeInAccruedExpense | -1.03M | -825.00K | 555.00K | 1.95M |
| ChangeInPayable | -1.59M | -853.00K | -1.18M | 973.00K |
| ChangeInAccountPayable | -1.59M | -853.00K | -1.18M | 973.00K |
| ChangeInPrepaidAssets | -1.36M | -1.07M | -170.00K | -134.00K |
| ChangeInReceivables | -1.56M | -308.00K | 3.41M | -1.11M |
| ChangesInAccountReceivables | 0.00 | 2.50M | -500.00K | |
| StockBasedCompensation | 14.55M | 14.80M | 13.35M | 11.07M |
| AmortizationOfSecurities | -4.39M | -5.99M | 152.00K | 673.00K |
| DepreciationAmortizationDepletion | 1.59M | 2.17M | 2.41M | 2.52M |
| DepreciationAndAmortization | 1.59M | 2.17M | 2.41M | 2.52M |
| Depreciation | 1.59M | 2.17M | 2.41M | 2.52M |
| NetIncomeFromContinuingOperations | -9.72M | -97.33M | -109.87M | -80.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FULC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|